AbbVie(ABBV 0.13%) reported second quarter 2025 results on July 31, 2025, delivering adjusted EPS of $2.97 (up$0.11 from guidance midpoint) and net revenues of $15.4 billion (up$400 million from expectations). Drug pipeline and deals reshape future growth profile Management raised full-year revenue guidance by $800 million, to$60.5 billion, and adjusted EPS (non- GAAP) guidance by $0.21 to a range of$11.88-$12.08, fueled by robust growth in immunology (SKYRIZI, RINVOQ) and neuroscience portfolios. The f ...